The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1127
ISSUE1127
April 1, 2002
Bosentan (Tracleer) for Pulmonary Arterial Hypertension
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Bosentan (Tracleer) for Pulmonary Arterial Hypertension
April 1, 2002 (Issue: 1127)
Bosentan (Tracleer - Actelion), a non-peptide endothelin receptor antagonist, has been approved by the FDA for oral treatment of patients who have pulmonary arterial hypertension (PAH) with symptoms of dyspnea at rest or with minimal exertion.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.